Related by context. All words. (Click for frequent words.) 77 tumor regression 71 evaluable patients 69 cytogenetic response 68 complete remissions 67 complete cytogenetic 67 cytogenetic responses 66 tumor recurrence 66 patients evaluable 66 heavily pretreated 66 liver metastases 65 neoadjuvant chemotherapy 65 partial remissions 65 chlorambucil 65 complete cytogenetic response 65 evaluable 65 FOLFOX4 65 pCR 65 heavily pretreated patients 65 tumor regressions 65 CR nPR 65 locoregional recurrence 64 PSADT 64 virologic response 64 remission CR 64 cabazitaxel 64 distant metastasis 64 chemoradiation 64 metastatic disease 64 preoperative chemotherapy 64 RECIST criteria 63 disease progression 63 metastatic lesions 63 sustained virologic response 63 bortezomib 63 CR CRu 63 metastatic renal cell carcinoma 63 decitabine 63 lung metastases 63 neoadjuvant 63 sustained virological response 63 metastatic RCC 63 postoperative chemotherapy 63 DMARD 63 brain metastases 63 free survival PFS 63 dasatinib 63 neoadjuvant therapy 63 chemoradiotherapy 62 median PFS 62 mg kg dose 62 CCyR 62 imatinib therapy 62 neurologic progression 62 carboplatin paclitaxel 62 FOLFOX 62 locoregional disease 62 adalimumab 62 pomalidomide 62 androgen deprivation 62 FOLFIRINOX 62 FOLFIRI 61 XELOX 61 temsirolimus 61 PASI scores 61 vandetanib 61 bone metastasis 61 radiographic progression 61 splenectomized patients 61 eribulin 61 tamoxifen therapy 61 placebo dexamethasone 61 lymph node involvement 61 olaparib 61 Doxil ® 61 oblimersen 61 Median survival 61 evaluable subjects 61 biochemical relapse 61 taxane therapy 61 advanced adenomas 61 5FU 61 nilotinib 61 ALND 61 DMARDs 61 EBRT 61 mycophenolate mofetil 61 annualized relapse 60 progression TTP 60 fluorouracil 60 temozolomide 60 binary restenosis 60 tumor resection 60 pazopanib 60 liver metastasis 60 plasma uric acid 60 HSCT 60 Flu Cy 60 recurrent GBM 60 Free Survival PFS 60 plus dexamethasone 60 tumor progression 60 HER2 positive breast cancer 60 pancreatic adenocarcinoma 60 azacitidine 60 distant metastases 60 metastases 60 RECIST 60 adjuvant therapy 60 axitinib 60 achieved ACR# 60 prednisone prednisolone 60 cisplatin chemotherapy 60 nab paclitaxel 60 irinotecan chemotherapy 60 relapsed SCLC 60 mRCC 60 MCyR 60 follicular lymphoma 60 mCRC patients 60 chemo radiotherapy 60 nonresponders 60 prospectively defined 60 prior chemotherapy regimens 59 EGFR TKI 59 HBeAg positive patients 59 Bezielle 59 gout flares 59 dose cohorts 59 HBeAg seroconversion 59 lymph node metastases 59 letrozole 59 anastrozole 59 basal cell carcinoma BCC 59 docetaxel chemotherapy 59 NNRTI resistance 59 KRAS wild 59 clinically meaningful 59 peginterferon alfa 2a 59 lung metastasis 59 androgen suppression 59 metastatic renal cell 59 trastuzumab Herceptin ® 59 hypercalcemia 59 antitumour activity 59 debulking surgery 59 biochemical recurrence 59 anthracycline taxane 59 mitoxantrone 59 cytoreduction 59 estramustine 59 leukemia AML 59 cetuximab 59 Kaplan Meier analysis 59 grade dysplasia 59 squamous histology 59 bevacizumab 59 locoregional 59 metastatic malignant melanoma 59 PSA nadir 59 chemotherapy gemcitabine 59 response CCyR 59 CRp 59 hematologic toxicity 59 virological response 59 teriflunomide 59 HER2 positive cancers 59 cytoreductive surgery 59 mapatumumab 59 recurrent VTE 59 androgen suppression therapy 59 R0 resection 59 metastatic prostate cancer 59 gefitinib 59 KRAS mutations occur 59 imatinib 59 nodular partial response 59 clinically meaningful improvement 59 sarcomatoid 59 fulvestrant 59 virologic failure 59 NSCLC 59 metastatic CRC 59 infarct size 59 Fludara 59 CYPHER Stent 59 tumors 59 clodronate 59 pegylated liposomal doxorubicin 59 5-fluorouracil/leucovorin 59 null responders 59 adjuvant chemotherapy 59 mTOR inhibitors 59 recurrent glioblastoma multiforme 59 viral kinetics 59 follicular lymphomas 59 EDSS scores 58 Tumor shrinkage 58 dacarbazine DTIC 58 TTF Therapy 58 FluCAM 58 receiving golimumab 58 sorafenib 58 CIMZIA ™ 58 thromboembolic events 58 virological failure 58 HER2 overexpression 58 RECIST Response Evaluation Criteria 58 paraprotein 58 #mg dose [002] 58 glycated hemoglobin levels 58 docetaxel 58 bendamustine 58 antitumor activity 58 NovoTTF 58 Response Evaluation Criteria 58 breast carcinoma 58 gemcitabine 58 adjuvant radiation 58 RRMS patients 58 cyclophosphamide 58 response pCR 58 zoledronic acid 58 anti leukemic 58 micrometastases 58 tumor necrosis 58 cystectomy 58 undetectable HBV DNA 58 metastatic GIST 58 intraocular inflammation 58 viral suppression 58 iniparib 58 mcg albinterferon alfa 2b 58 severe exacerbations 58 platinum refractory 58 bronchial thermoplasty 58 HER2 positive 58 achieved CCyR 58 durable remissions 58 relapsed MM 58 standard chemotherapy regimen 58 adjuvant radiotherapy 58 DAPT 58 trastuzumab 58 rituximab 58 APTIVUS r 58 definite stent thrombosis 58 EGFR mutations 58 gemcitabine carboplatin 58 cediranib 58 refractory AML 58 histologically confirmed 58 indolent NHL 58 5-FU/LV 58 topotecan 58 inflammatory lesions 58 febrile neutropenia 58 FOLPI 58 certolizumab 58 stage IIIB 58 lymphocytosis 58 ACR# response 58 Folfox 58 dose limiting toxicities 58 dacarbazine 58 CIMZIA TM 58 amrubicin 58 repigmentation 58 IV NSCLC 58 abiraterone 58 mg/m2 dose 58 infliximab 57 ACR# responses 57 bowel resection 57 dose cohort 57 TNF antagonist 57 carcinoid 57 interferon alfa 57 tocilizumab 57 CRu 57 Irinotecan 57 achieved sustained virological 57 liver histology 57 adenoma 57 CMV disease 57 nonmelanoma skin cancers 57 underwent resection 57 xenograft models 57 goserelin 57 DFMO 57 Amrubicin 57 sunitinib 57 NLX P# 57 undetectable viral load 57 visceral metastases 57 GIST tumors 57 SUVmax 57 mammary tumors 57 reinfarction 57 Thal Dex 57 antiangiogenic therapy 57 HER2 positive metastatic breast 57 trabectedin 57 gemcitabine Gemzar 57 carotid stenosis 57 adriamycin 57 plus gemcitabine 57 FLT3 ITD 57 intravenous bisphosphonates 57 ximelagatran 57 fluvastatin 57 androgen ablation 57 medullary thyroid cancer 57 GVAX 57 gemcitabine chemotherapy 57 QTc prolongation 57 Solid Tumors criteria 57 unresectable stage 57 MGd 57 overlapping toxicities 57 mg BID 57 abiraterone acetate 57 antitumor effect 57 recurrent NSCLC 57 neoadjuvant treatment 57 nodal metastases 57 systemic ALCL 57 colorectal tumors 57 placebo 57 melphalan prednisone 57 ACTEMRA 57 metastatic lung cancer 57 FOLFOX6 57 atheroma volume 57 etanercept 57 bone metastases 57 mutated KRAS 57 histologically proven 57 ALT flares 57 octreotide 57 hormonal therapy 57 imetelstat 57 TEAEs 57 undetectable HCV RNA 57 MACCE 57 Median progression 57 LVEF 57 HGS ETR1 57 secondary efficacy endpoints 57 alemtuzumab treated 57 relapsing remitting 57 TACE 57 axillary dissection 57 lymphadenectomy 57 iniparib BSI 57 dacarbazine chemotherapy 57 carboplatin 57 ipsilateral stroke 57 HER2 positive tumors 57 Ophena TM 57 achieved PASI 57 CA4P 57 glioblastoma tumors 57 relapsers 57 epithelial tumors 57 epithelial ovarian cancer 57 asymptomatic carotid stenosis 57 plus methotrexate 57 peginterferon 57 unresectable 57 cardiac dysfunction 57 rapid virologic response 57 IIIB NSCLC 57 CANCIDAS 56 allogeneic stem cell 56 low dose cytarabine 56 KRAS status 56 mucosal healing 56 Partial Responses 56 adenomatous polyps 56 retinal thickness 56 erlotinib 56 radical nephrectomy 56 cilengitide 56 stage IIIB IV 56 BRAF mutations 56 renal tumors 56 cardiac toxicity 56 colorectal liver metastases 56 ibandronate 56 interferon beta therapy 56 ovarian carcinoma 56 chemotherapeutic regimens 56 pneumonectomy 56 refractory NSCLC 56 glufosfamide 56 adenoma recurrence 56 angiographic restenosis 56 severe neutropenia 56 IMGN# 56 proteinuria 56 secondary endpoint 56 detectable HCV RNA 56 epirubicin 56 doxorubicin docetaxel 56 T#I mutation 56 imiquimod 56 TMC# r 56 hormone deprivation 56 ponatinib 56 endometrial carcinoma 56 Taxotere ® 56 operable breast cancer 56 aminotransferases 56 dose dexamethasone 56 paroxysmal AF 56 bevacizumab Avastin 56 relapsing MS 56 Pemetrexed 56 Solid Tumors RECIST 56 Partial Response 56 differentiated thyroid 56 timepoint 56 ACTEMRA TM 56 metastatic melanoma 56 HER2 negative 56 clinically meaningful improvements 56 genotypic resistance 56 HBV DNA 56 crizotinib PF # 56 exemestane 56 afatinib 56 chemotherapy regimen 56 plus MTX 56 dexamethasone Decadron 56 hematologic 56 chronic lymphocytic leukemia CLL 56 interferon ribavirin 56 dosing cohort 56 statistically significant improvement 56 oral clodronate 56 methotrexate 56 mg ustekinumab 56 neoadjuvant radiation 56 receiving APTIVUS r 56 pertuzumab 56 CoFactor 56 discontinuations due 56 circulating EPCs 56 panitumumab 56 idraparinux 56 histologic 56 Xelox 56 anti TNF 56 daunorubicin 56 advanced NSCLC 56 proliferative diabetic retinopathy 56 erlotinib Tarceva 56 achieve sustained virologic 56 superficial bladder cancer 56 comparator arm 56 vinorelbine 56 ZOLINZA 56 Carboplatin 56 metastatic malignant 56 oral Xeloda 56 HBeAg positive 56 MabCampath 56 molecular remissions 56 avosentan 56 untreated mice 56 dose cytarabine 56 moderate renal impairment 56 methotrexate therapy 56 CIN3 56 trabedersen 56 antitumor effects 56 dose escalation phase 56 relapsed MCL 56 DAS# remission 56 ErbB2 positive 56 HNSCC 56 cytokine refractory 56 ACZ# 55 relapsed myeloma 55 contralateral breast 55 rindopepimut 55 A1c levels 55 relapsed ovarian cancer 55 vismodegib 55 remission induction 55 octreotide LAR 55 trastuzumab DM1 55 radioiodine therapy 55 small lymphocytic lymphoma 55 serum phosphate 55 KRAS mutations 55 HBeAg negative patients 55 morphometric vertebral fractures 55 myeloablative 55 prostate cancer CRPC 55 perioperative complications 55 alkylating agent 55 HCV RNA 55 ARB telmisartan 55 clinically localized prostate 55 SCCHN 55 eplerenone 55 myelosuppression 55 uric acid lowering 55 ruboxistaurin 55 atypical hyperplasia 55 surrogate endpoint 55 mg kg cohorts 55 gastrointestinal stromal tumor GIST 55 infarcts 55 intravenous cyclophosphamide 55 thymoma 55 standard chemotherapy regimens 55 Toxicities 55 orchiectomy 55 riociguat 55 folinic acid 55 anti EGFR antibody 55 sentinel lymph node biopsy 55 endometrial hyperplasia 55 parathyroidectomy 55 IGF 1R 55 pegylated interferon alpha 55 cisplatin 55 methotrexate MTX 55 immunosuppression 55 low dose dexamethasone 55 tumor progression TTP 55 virologic responses 55 dosing cohorts 55 thalidomide Thalomid 55 NATRECOR R 55 ischemic cardiomyopathy 55 EGFR mutation positive 55 Subgroup analysis 55 resected pancreatic cancer 55 4mg/kg 55 H. pylori eradication 55 dasatinib Sprycel 55 mitoxantrone chemotherapy 55 degarelix 55 surgical debulking 55 oral Hycamtin 55 malignant lesions 55 tyrosine kinase inhibitors 55 histologically 55 adrenalectomy 55 endometrial cancers 55 mammographic density 55 anthracycline containing 55 relapsed refractory multiple myeloma 55 GISTs 55 8mg/kg 55 posaconazole 55 neutrophil counts 55 rosuvastatin #mg 55 squamous cell carcinoma SCC 55 LHRH agonists 55 pegylated interferon 55 recurrent glioblastoma 55 hepatic metastases 55 HbA1c levels 55 BRAF inhibitor 55 malignant pleural mesothelioma 55 CHOP chemotherapy 55 bosentan 55 composite endpoint 55 virologic breakthrough 55 colectomy 55 adenocarcinomas 55 sulfasalazine 55 grade gliomas 55 % CI #.#-#.# [003] 55 trastuzumab Herceptin R 55 XIENCE V PROMUS Stent 55 liver resection 55 recanalization 55 recurrences 55 prior relapsers 55 irinotecan 55 seminoma 55 #mg BID [001] 55 anaplastic 55 glargine 55 castration resistant prostate cancer 55 ixabepilone 55 apremilast 55 ipsilateral breast 55 biliary tract cancer 55 severe psoriasis 55 adjuvant colon cancer 55 leucovorin 55 MS relapses 55 telomerase inhibition 55 endoscopic remission 55 imatinib Gleevec 55 stage IIIb 55 VT VF 55 TIMP 1 55 gemcitabine cisplatin 55 OAB symptoms 55 sorafenib Nexavar 55 FOLFIRI alone 55 Adjuvant chemotherapy 55 concurrent chemoradiation 55 simvastatin ezetimibe 55 paricalcitol 55 liposomal doxorubicin 55 ER CHOP 55 tiotropium 55 relapsed CLL 55 seminomas 55 renal cell carcinomas 55 fondaparinux 55 BRAF mutation 55 SCIg 55 NMIBC 55 lung tumors 55 cancer mCRC 55 antiandrogen 55 tamoxifen 55 clinically meaningful differences 55 Cytoxan 55 elotuzumab 55 placebo controlled trials 55 seropositive patients 55 receptor tyrosine kinase inhibitor 55 mcg BID 55 mg QD 55 PEGylated interferon beta 1a 55 cranial radiation 55 dysplasia 55 paclitaxel eluting stents 55 Hepatocellular Carcinoma HCC 55 allogeneic SCT 55 LHRH analogues 55 elacytarabine 55 PXD# 55 adenocarcinoma 55 mcg kg 55 chemotherapy regimens 55 vertebral fracture 55 platelet inhibition 55 familial ALS 55 serum calcium levels 55 ASA# 55 timepoints 55 Dasatinib 55 tapentadol ER 55 prior nephrectomy 55 HCV genotype 55 Neoadjuvant 55 baseline HbA1c 55 refractory CTCL 55 tolvaptan 55 Navelbine 55 VADT 55 chemotherapy docetaxel 55 underwent surgical resection 55 VcMP 55 flutamide 55 HGPIN 55 hepatic fibrosis 55 placebo controlled clinical trials 55 sorafenib Nexavar ® 55 stent thromboses 55 bortezomib refractory 55 glioblastomas 55 galiximab 55 serum phosphorus 55 olmesartan 55 serum clusterin levels 54 intracranial hemorrhage ICH 54 blastic phase 54 adenomas 54 refractory CLL 54 remyelination 54 ribavirin therapy 54 anterior uveitis 54 azacytidine 54 relapsed GBM 54 immune reconstitution 54 doxorubicin cyclophosphamide 54 lymph node dissection 54 prostate cancer CaP 54 receiving highly emetogenic 54 postoperative radiotherapy 54 advanced adenoma 54 colon tumors 54 liver transplant recipients 54 generalized seizures 54 breast tumors 54 dasatinib Sprycel ® 54 EVIZON 54 lymphomas 54 receiving VICTRELIS 54 bevacizumab Avastin ® 54 medically inoperable 54 methotrexate monotherapy 54 graft occlusion 54 recurrent GBM patients 54 taxane chemotherapy 54 endocrine therapy 54 ipilimumab 54 dose escalation 54 oophorectomy 54 WBRT 54 invasive carcinomas 54 phase IIb study 54 refractory multiple myeloma 54 Tarceva erlotinib 54 pramipexole 54 favorable pharmacokinetic profile 54 seroconversion 54 aromatase inhibitor 54 stent implantation 54 chemoresistant 54 radiochemotherapy 54 bicalutamide 54 adalimumab Humira 54 palliation 54 darapladib 54 curative resection 54 Psoriasis Area 54 log# IU mL 54 Seliciclib 54 EGFR inhibitors 54 PROSTVAC VF 54 baseline LDH 54 OncoVEX GM CSF 54 GnRH agonists 54 resistant ovarian cancer 54 oral FTY# 54 interferon therapy 54 secondary efficacy endpoint 54 cisplatin gemcitabine 54 axillary lymph nodes 54 oxycodone CR 54 ELOXATIN 54 chronic GVHD 54 active comparator 54 TORISEL 54 azathioprine 54 prostate tumor 54 axillary node dissection 54 Cotara 54 reintervention 54 moderately emetogenic 54 basal cell carcinomas 54 HPV-#/# 54 paclitaxel carboplatin 54 HBeAg 54 Halaven 54 sUA 54 teriparatide 54 LEXIVA r 54 hyperoxaluria 54 chemotherapy cisplatin 54 Jevtana 54 metastatic castration resistant 54 HBeAg negative 54 antihypertensive therapy 54 mg dose 54 elagolix 54 ovarian tumors 54 pT2 54 nonmetastatic prostate cancer 54 ADAGIO study 54 Zevalin consolidation 54 Median PFS 54 precancerous lesions 54 lamotrigine 54 lymphoma CTCL 54 trials RCTs 54 elevated ALT 54 hematologic adverse 54 ALA PDT 54 anti angiogenic therapy 54 serum urate 54 enzastaurin 54 tipranavir 54 indolent lymphomas 54 IFN α 54 nephrectomy 54 fibrinolysis 54 lumbar spine BMD 54 pT3 54 viral kinetic 54 alicaforsen enema 54 gastrointestinal stromal tumors GIST 54 neostigmine 54 EGFr 54 external beam radiotherapy 54 lenalidomide dexamethasone 54 invasive lobular carcinoma 54 regorafenib 54 postoperative complication 54 rotigotine 54 EXJADE 54 nonfatal MI 54 Aptivus ® 54 docetaxel prednisone 54 otamixaban 54 adjuvant cisplatin 54 tenecteplase 54 desvenlafaxine succinate 54 metastatic cancer 54 EBMT criteria 54 neointimal hyperplasia 54 papillary renal cell carcinoma 54 Tarceva TM 54 uveal melanoma 54 DLBCL 54 dexamethasone 54 baminercept 54 HuMax EGFr 54 idarubicin 54 log# copies mL 54 Cisplatin 54 B7 H3 54 SLNB 54 severe hypersensitivity reactions 54 peg interferon 54 PCa 54 #Gy 54 mucinous 54 androgen independent 54 BEACOPP 54 pediatric acute lymphoblastic 54 hepatocellular carcinomas 54 MitraClip device 54 fibrinolytic 54 systemically administered 54 pemetrexed 54 abatacept 54 unresectable tumors 54 tanespimycin 54 glioblastoma 54 axillary nodes 54 metastatic colorectal cancer 54 axillary node 54 cetuximab Erbitux 54 DOXIL 54 adefovir 54 thrombotic complications 54 INC# 54 ZYBRESTAT 54 prolongs survival 54 imatinib resistant 54 zalutumumab 54 neovascular 54 FOLPI regimen 54 anemia hemoglobin 54 TOP2A 54 interferon alfa 2b 54 cranial irradiation 54 grade glioma 54 nucleoside naive patients 54 Complete Response CR 54 chemoradiation therapy 54 SUTENT 54 telaprevir dosed 54 peginterferon alfa 2b 54 pre cancerous lesions 54 nodal metastasis 54 leukaemias 54 GOUT 54 Herceptin trastuzumab 54 biologic therapy 54 resectable 54 Torisel 54 lumiliximab 54 HCV infected 54 serous ovarian cancer 54 events SAEs 54 REYATAZ r arm 54 PLX# 54 AVODART 54 recurrent prostate cancer 54 ritonavir boosted 54 erlotinib Tarceva ® 54 invasive ductal 54 ABSORB trial 54 elevated LDH 54 statistically significant p = 54 ACUITY trial 54 PegIFN RBV 54 neuroendocrine tumors 54 endophthalmitis 54 pregabalin 54 ifosfamide 54 Metastatic 54 refractory acute myeloid 54 metastatic tumors 54 pulmonary toxicity 54 irbesartan 54 beta blocker therapy 54 neointimal 54 micafungin 54 parkinsonian symptoms 54 bezafibrate 54 VIDAZA 54 stable angina 54 lymph node metastasis 54 osteosarcomas 54 Subgroup analyzes 53 colorectal carcinomas 53 rebleeding 53 melanoma tumors 53 refractory CML 53 postoperative mortality 53 plus ribavirin 53 F FDG PET 53 lupus nephritis 53 alemtuzumab 53 TKI therapy 53 steroid dexamethasone 53 exacerbations 53 nitazoxanide 53 eribulin mesylate 53 thyroid carcinoma 53 biologic DMARD 53 levodopa therapy 53 virologic 53 relapsing remitting MS 53 Trastuzumab 53 adjuvant tamoxifen 53 haematologic 53 estrogen receptor negative 53 renal toxicity 53 systemic corticosteroid 53 % CI #.#-#.# [007] 53 fludarabine 53 briakinumab 53 platelet reactivity 53 serum phosphate levels 53 efficacy endpoint 53 thrombocytopenic 53 metastatic kidney 53 IOP lowering 53 radical prostatectomy RP 53 CIN2 + 53 rtPA 53 lymphopenia 53 breast conserving 53 FDG uptake 53 thyroglobulin 53 tumor 53 achieved statistical significance 53 LY# [003] 53 cisplatin vinorelbine 53 ertapenem 53 T2DM 53 raltegravir 53 relapsed AML 53 cytologically confirmed 53 systemic absorption 53 Tamibarotene 53 cytopenias 53 fibrosis 53 microtubule targeting 53 colorectal carcinoma 53 doxorubicin 53 Natalizumab 53 serum PSA 53 renal dysfunction 53 paclitaxel cisplatin 53 refractory ovarian cancer 53 INCB# [003] 53 serum urate levels 53 papillary thyroid carcinoma 53 seliciclib 53 antibiotic rifaximin 53 tumor lysis syndrome 53 FTY# 53 plasma HCV RNA 53 everolimus eluting stents 53 gastrointestinal stromal tumors 53 anthracycline 53 anti androgen 53 ISEL 53 adverse cytogenetics 53 #F FDG PET 53 PROMACTA 53 relapsing remitting multiple sclerosis 53 adjunctive ABILIFY 53 SVR# 53 serum HCV RNA 53 completely resected 53 Aflibercept 53 microbiological eradication 53 T#I [002] 53 Gemcitabine 53 Bortezomib